# Potenza Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/potenza-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Cambridge, US
- Website: www.potenzatherapeutics.com
- Total disclosed funding: $15M
- Latest round: Series A (Dec 2, 2014)
- Investors on record: 3

## About

Potenza Therapeutics, Inc. is a U.S.-based biopharmaceutical company focusing on innovative therapeutic solutions to enhance healthcare outcomes for chronic illnesses through advanced research methodologies.Founded in 2013 in Cambridge, US, Potenza Therapeutics, Inc. specializes in developing advanced biopharmaceuticals. The company was acquired by Astellas Pharma in December 2018 for up to USD 404.7 mn, which included an upfront payment of USD 164.6 mn. The acquisition is intended to leverage cutting-edge science and technology for innovative medicine development.Potenza Therapeutics offers a variety of therapeutic solutions aimed at addressing chronic health conditions through innovative methodologies. Its core product line features advanced biopharmaceuticals developed from cutting-edge research, focusing on personalized medicine tailored to individual patient needs. The products are marketed mainly in North America and Europe, targeting healthcare providers such as hospitals, clinics, and specialty care providers, contributing to improved health management.The revenue model for Potenza Therapeutics is built around direct transactions with healthcare providers and institutions that utilize its therapeutic products. The company employs a business-to-business (B2B) approach, allowing hospitals and clinics to purchase innovative therapies for their treatment protocols, with a tiered pricing strategy for bulk purchasing. This model fosters long-term partnerships with clients dedicated to enhancing patient care.Following its acquisition by Astellas Pharma, Potenza Therapeutics aims to expand its product offerings and market reach. The company plans to develop new therapeutic products leveraging recent funding to enhance its research capabilities. Specific plans for market expansion include targeting additional healthcare markets in Europe and North America by 2025. The recent acquisition will also facilitate the integration of advanced technologies, aimed at delivering innovative medicines that add value for patients.

## Funding rounds

- Series A, Dec 2, 2014, $15M — InterWest Partners, Astellas Venture Management, MPM BioImpact

## Investors

- InterWest Partners (https://capitalatlas.ai/funds/interwest-partners) — Series A
- Astellas Venture Management (https://capitalatlas.ai/funds/astellas-venture-management) — Series A
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series A